1. Annual European Medical-Scientific Conference on Morgellons Disease | July 11, 2018

The Charles E. Holman Morgellons Disease Foundation in collaboration with the BCA-clinic presents:

1. Annual European Medical-Scientific Conference on Morgellons Disease

20th October 2018, Augsburg, Germany

Morgellons disease is a bizarre skin condition associated with tickborne disease. It is characterised by disfiguring skin lesions containing multicoloured filaments, often accompanied by fatigue, joint and muscle pain and neurological problems.

We proudly present the following speakers:

  • Cindy Casey-Holman, RN Director of CEHMDF
  • Ginger Savely, DNP, MSN, Med, FNP
  • Carlo Maria Mortellaro, DVM, Prof. of Veterinary Surgical Pathophysiology
  • Marianne Middelveen, MSc, MDes
  • Carsten Nicolaus, MD, PhD, Director and Founder of BCA-clinic
  • Huib Kraaijeveld, Human Rights and WHO

 

Expect the latest on Morgellons disease including updates on diagnosis, treatment and research.

For more information click here!

Agenda click here!

Save your seat click here!



BCA-research team detects tick carrying Borrelia miyamotoi in Augsburg | February 20, 2018

During the last years, a certain type of Borrelia of Asian origin has been detected in only a few places across Europe and the US. In Asia, Borrelia miyamotoi is well-known as cause of relapsing fevers and pain. In Germany Borrelia miyamotoi has been scientifically verified at Lake Constance and near Munich up to now. Most recently the BCA-research team identified Borrelia miyamotoi DNA in a common local tick in our local tick studies at Augsburg.

For full research abstract, please check: http://link.springer.com/article/10.1007/s10493-018-0220-8

Picture: Using the specific PCR, the scientist can identify different species of Borrelia based on the size of the band on the Agarose-gel.

For getting the whole paper please download directly at Springer Medien site (fee-based). In case of any further questions, please contact: forschung@bca-lab.de.



Gesucht: Mitarbeiter/in Verwaltung im Patientenkontakt | February 16, 2018

Die BCA-clinic ist eine auf durch Zecken-übertragene Erkrankungen spezialisierte Privatklinik. Seit über 10 Jahren werden Patienten mit chronischen Infektionen im Bereich der Therapie und Diagnostik betreut. Das Unternehmen arbeitet eng mit der Privatpraxis Dr. Nicolaus zusammen. Die BCA-clinic vereint unter ihrem Dach das Servicelabor BCA-lab, ein Forschungslabor und eine Tagesklinik. Circa 70 Prozent der Patienten kommen aus dem Ausland.

 

Aufgabengebiet:

  • Direkter und telefonischer Patientenkontakt in deutscher, englischer und ggf. französischer Sprache
  • Beratung der Patienten zum Leistungsangebot der BCA-clinic Augsburg und des BCA-lab
  • Dokumentation in deutscher Sprache im elektronischen Patientenverwaltungssystem TurboMed
  • Organisatorische Vor- und Nachbereitung von Patientengesprächen
  • Terminvereinbarungen
  • Rechnungserstellung

 

Anforderungsprofil:

  • Berufsausbildung als Medizinische Fachangestellte (Arzthelferin o.ä.)
  • solide englische und idealerweise französische Sprachkenntnisse (in Wort und Schrift)
  • wünschenswert: eine weitere Fremdsprache
  • QM und Turbomed Kenntnisse wünschenswert
  • bei Quereinsteigern wünschenswert: medizinische Grundkenntnisse

 

Bewerbungen von Quereinsteigern (wie Dolmetscher, Sprachlehrer, Hotelfachangestellte mit fundierten sprachlichen Kenntnissen in Französisch und Englisch) sind ebenfalls willkommen. Bei Quereinsteigern stehen die Fremdsprachenkenntnisse im Vordergrund, an zweiter Stelle stehen Kenntnisse im Gesundheitswesen, die für die Arbeit notwendig sind.

 

Außerdem sollte der/die neue Mitarbeiter/in teamfähig und begeisterungsfähig sein. Es wird ein engagiertes Selbststudium in der Thematik der durch Zecken-übertragenen Erkrankungen sowie die Teilnahme an Fortbildungen erwartet.

Die ausgeschriebene Stelle ist ab sofort in Vollzeit zu besetzen.

 

Für Rückfragen steht Ihnen ab dem 21. Februar folgende Ansprechpartnerin zur Verfügung:

Frau Daniela Garba        Tel.: +49 (0) 821 455 471 – 60

 

Bitte senden Sie Ihre vollständigen Bewerbungsunterlagen unter Angabe Ihrer Gehaltsvorstellung und des nächstmöglichen Eintrittstermins per E-Mail an:

 

bewerbung@bca-clinic.de



Opening hours BCA-lab during festive season | December 04, 2017

This is an important note for all people wanting to send blood samples for lymetest:

Patients/physicians who are intending to send blood samples to our BCA-lab, please ensure they will arrive in good time!

Due to public holidays the samples will need to be with us by 22nd December the latest or between 27th and 29th December.

From 2nd January our laboratory services will be running as usual.



New Laboratory method: DNA-PCR | January 27, 2016

DNA-PCR Test for Borrelia gets Increase in Speed and Sensitivity

 

From February 1st 2016, the BCA-lab will offer a new DNA-PCR test that delivers results faster to our clients and is more sensitive as compared to its predecessors.

 

The test will use blood or tissue/biopsy material to search for the most important species of Borrelia burgdorferi, including Borrelia miyamotoi and Bartonella spp.

The test for Borrelia is based on consecutive PCR reactions, which means that different pathogen genes can be detected on a highly specific and sensitive level. The repertoire of molecular biological detection at the BCA-lab is complemented by a PCR-based Bartonella-Assay.

The research team that developed this in-house PCR test method is led by Dr. Viktoria Krey (Molecular Biologist).

We are now able to produce results within 14 days of conducting the test; you can order the necessary test kits in our laboratory.

 

phone: +49 (0) 821 455 9820
email: info@bca-lab.de

 

For more detailed questions please don’t hesitate to contact us on: pcr@bca-lab.de

Read more here!



LymeSpot Revised: The new generation EliSpot | April 17, 2015

EliSpot is used to detect an infection of Borrelia and its co-infections on a cellular level. It is trustworthy and we have now been using it for several years. The first generation of enzymatic EliSpots determined the interferon-gamma production of cells and provided vital information about the infection. We have now developed this test even further.

The new EliSpot, ‘LymeSpot Revised’, delivers detailed information about the activity of the infection and/or inflammation. This test can better differentiate between an active (specific effector-cells) or latent (specific memory-cells) infection. As a result, it is now possible to evaluate whether it is an infection, inflammation or autoimmune processes that are prevailing. In comparison with EliSpot, which is based on the production of interferon-γ, LymeSpot also determines the levels of cytokine IL-2.

For more information, click here

On the 12th of February 2015, a new study was published that demonstrates the clinical benefits of the therapeutic approach by EliSpot Assay in identifying the two cytokines Gamma-Interferon and Interleukin-2 amongst patients with acute and chronic Q-fever. Q-fever is also a tick-borne disease. You can find this study here.